SUNNYVALE, Calif.--(BUSINESS WIRE)--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it will showcase the first live case demonstration by transmission in the USA of its breakthrough DESolve® NXT Novolimus Eluting Bioresorbable Coronary Scaffold System at the 28th annual Transcatheter Cardiovascular Technologies (TCT) Conference in Washington, DC on Sunday, October 30. The Elixir-sponsored symposium is also scheduled for Sunday, October 30th from 6-8 PM.
Elixir will announce new six-month data for its 120µm thin-strut DESolve Cx Fully Bioresorbable Novolimus Eluting Coronary Scaffold System and the four-year data on the DESolve Novolimus eluting scaffold during the scientific conference. Following are the details of Elixir Medical’s programs and activities at TCT in Eastern Standard Time (EST):
Saturday, October 29:
6:00 – 8:00 PM, Washington Convention Center Hall B, Lower Level
Challenging
Case: An 80-year-old patient with multiple metal allergies and a
bifurcation lesion treated with DESolve (included kissing balloon).
Practical
Solution: Can Bioresorbable Scaffold (BRS) be the treatment for a
different BRS Restenosis and Bioresorbable Scaffold Recoil?
Sunday, October 30:
10:30 AM, Washington Convention Center, Main Arena
LIVE CASE
from Antwerp Cardiovascular Centre, ZNA, Antwerp, Belgium, by Stefan
Verheye, MD, PhD
Fully Bioresorbable DESolve® NXT
Novolimus Eluting Coronary Scaffold System
Sunday, October 30:
6 – 8 PM, Marriott Marquis Ballroom, Salon 6, Level M2
Elixir-sponsored
Symposium:
DESolve® NXT – The Next
Breakthrough in BRS Innovation
Chairs
- Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil
- Martin B. Leon, MD, New York – Presbyterian Hospital / Columbia University Medical Center, New York, NY, USA
- Roxana Mehran, MD, Mount Sinai Hospital, New York, NY, USA
Panelist Faculty
- Niels R. Holm, MD, Aarhus University Hospital, Aarhus N, Denmark
- Holger Nef, MD, PhD Head of the Cardiac Catheterization Laboratory, University Hospital Giessen, Giessen, Germany
- Jack Wei Chieh Tan, MD, National Heart Centre Singapore, Singapore
Agenda
- Session Objectives
- DESolve Evolution – DESolve, Cx, NXT, NXT Plus
- DESolve Nx 4-year follow-up
- DESolve Cx 6-month follow-up
- DESolve Real World: Europe experience
- DESolve Real World: Asia experience
- BIFSORB
- Indication-specific BRS Therapies – AMITY, PRAVA
- Session Key Learning
Space is limited: Please register in advance at http://www.crf.org/tct/agenda/satellite-programs
Monday, October 31:
Device Specifications and Clinical Program Update
10:34 AM, Washington Convention Center, Room 305, Level 3
DESyne
BD: TCT 32: Prospective, Multi-Center Evaluation of the DESyne BD
Novolimus-Eluting Coronary Stent: 4-year clinical results.
Ricardo
Costa, MD, PhD, Instituto Dante Pazzanese de Cardiologia, Sao Paulo,
Brazil
12:45 PM, Washington Convention Center, Room 103B, Level 1
DESolve:
TCT 32: Prospective, Multi-Center Evaluation of the DESolve
Novolimus-Eluting Bioresorbable Coronary Scaffold: Imaging Outcomes and
Four-Year Clinical and Imaging Results
Alexandre Abizaid, MD, PhD,
Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil
4:22 PM, Washington Convention Center Room 151, Level 1
DESolve
NXT, Cx and AMITY: Unique properties and results from 150 µm To 120
µm.
Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese de
Cardiologia, Sao Paulo, Brazil
Tuesday, November 1:
10:14 AM, Washington Convention Center Room 103B, Level 1
CASE
#9: Value of self-expanding properties using DESolve BRS in a
bifurcation
Niels R. Holm, MD, Aarhus University Hospital, Aarhus
N, Denmark
2:00 PM, Washington Convention Center Room 207, Level 2
Alexandre
Abizaid, MD, PhD, Instituto Dante Pazzanese de Cardiologia, Sao Paulo,
Brazil
DESolve: Impact of Different PLLA Polymers and BRS
Construction on Implant Technique: From Absorb to DESolve to Fantom to
Manli and More
7:22 PM, Marriott Marquis, Salon 1-4, Level M2
Alexandre
Abizaid, MD, PhD, Instituto Dante Pazzanese de Cardiologia, Sao Paulo,
Brazil
DESolve: Thin Struts With Self-Correcting Property
(DESolve)
Elixir Medical will have a booth at TCT: Booth 1309, Exhibit Hall. The booth will be open Sunday, October 30 and Monday, October 31 from 9 am to 5 pm, and Tuesday, November 1 from 9 am to 2 pm.
About Elixir Medical
Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, California, develops products that combine state-of-the-art medical devices with advanced pharmaceuticals to provide innovative treatment solutions to patients worldwide. The company's next-generation drug-eluting stent systems and bioresorbable coronary scaffold are designed to optimize localized drug delivery to provide safe and effective treatments for cardiovascular patients. For more information, visit www.elixirmedical.com.